Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cirrhosis

Cirrhosis

Subtypes of Cirrhosis

Primary biliary cholangitis 8 Liver Fibrosis 7 Decompensated liver cirrhosis 6 Fibrosis 4 Compensated cirrhosis 3 Keloid 2 Acute decompensation of cirrhosis 1 Compensated MASH cirrhosis 1 Decompensated liver failure 1 End-stage liver disease 1

47 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cirrhosis

82 trials tracked for Cirrhosis: 27 in phase 3 or 4 and 2 with published results. The most-cited published study has 45 citations.

82Trials tracked
27Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 12 Phase 3 15 Phase 2 22 Phase 1 3 Other / NA 30
  1. Phase 4 The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Completed · 45 cited
  2. Phase 3 Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Completed · 15 cited
  3. Phase 4 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed
  4. Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics Completed
  5. Phase 4 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant Completed
  6. Phase 4 Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis Completed
Show 44 more trials
  1. Phase 4 Ramelteon for Treatment of Insomnia in Cirrhosis Completed
  2. Phase 4 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed
  3. Phase 4 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Completed
  4. Phase 4 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis Completed
  5. Phase 4 Tolvaptan for Ascites in Cirrhotic Patients Completed
  6. Phase 4 Steroid Free Immunosuppression in Liver Transplantation Completed
  7. Phase 4 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed
  8. Phase 3 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection Completed
  9. Phase 3 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study Completed
  10. Phase 3 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients? Completed
  11. Phase 3 A Trial to Improve Quality of Life in People With Cirrhosis Completed
  12. Phase 3 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Completed
  13. Phase 3 Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) Completed
  14. Phase 3 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis Completed
  15. Phase 3 Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) Completed
  16. Phase 3 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema Completed
  17. Phase 3 PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) Completed
  18. Phase 3 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema Completed
  19. Phase 3 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg Completed
  20. Phase 3 Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis Completed
  21. Phase 3 Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) Completed
  22. Phase 2 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Completed
  23. Phase 2 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients Completed
  24. Phase 2 FMT in Cirrhosis and Hepatic Encephalopathy Completed
  25. Phase 2 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation Completed
  26. Phase 2 A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy Completed
  27. Phase 2 A Study of IDN-6556 in Subjects With Liver Cirrhosis Completed
  28. Phase 2 A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Completed
  29. Phase 2 VE303 for Treatment of Hepatic Encephalopathy (HE) Completed
  30. Phase 2 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Completed
  31. Phase 2 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Completed
  32. Phase 2 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Completed
  33. Phase 2 A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients Completed
  34. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  35. Phase 2 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C Completed
  36. Phase 2 Human Fetal Liver Cell Transplantation in Chronic Liver Failure Completed
  37. Phase 2 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study Completed
  38. Phase 2 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Completed
  39. Phase 2 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema Completed
  40. Phase 2 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Completed
  41. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  42. Phase 2 MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Completed
  43. Phase 2 [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer Completed
  44. Phase 1 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis Completed

Showing the 50 most-cited and recently-updated of 82 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
Gastroenterology Meta-analysis
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…
Apr 9, 2026
Hospitalized malignant neoplasm patients show high comorbidity burden and distinct disease patterns across 163 Chinese hospitals
Oncology Cohort
Hospitalized malignant neoplasm patients show high comorbidity burden and distinct disease patterns across 163 Chinese hospitals Hospitalized cancer patients in China often have other serious health conditions
This retrospective cohort study examined 107,029 hospitalized patients with malignant neoplasms across 163 hospitals in Zhanjiang, China.
Hospitalized cancer patients in China often face five other serious health conditions, with rural residents, men, and those aged 65 or older…
Frontiers Apr 9, 2026
First-in-human study finds VS-01 generally well tolerated in decompensated cirrhosis with ascites
Gastroenterology Phase I
First-in-human study finds VS-01 generally well tolerated in decompensated cirrhosis with ascites Early safety study of VS-01 infusion in 12 patients with advanced liver disease
This phase 1b, open-label, non-randomized study in 12 patients with decompensated cirrhosis, ascites, and covert hepatic encephalopathy foun…
A new liver treatment called VS-01 was safe for patients with advanced disease, causing mostly mild stomach issues in an early study of 12 p…
Apr 9, 2026
Oral nutritional interventions associated with reduced clinical events in adults with cirrhosis
Gastroenterology Meta-analysis
Oral nutritional interventions associated with reduced clinical events in adults with cirrhosis Can better nutrition help people with advanced liver disease?
A systematic review and meta-analysis of 3,128 adults with cirrhosis found oral nutritional interventions were associated with reduced risks…
Better nutrition linked to fewer hospital visits and lower risk of serious problems for adults with advanced liver disease.
Apr 8, 2026
Novel nomogram predicts long-term survival after TIPS in decompensated cirrhosis
Nephrology Cohort
Novel nomogram predicts long-term survival after TIPS in decompensated cirrhosis Can we better predict survival for cirrhosis patients getting TIPS treatment?
A retrospective single-center cohort study of 409 patients with decompensated cirrhosis undergoing first TIPS developed and validated a nomo…
A new prediction tool outperforms standard scores at estimating how long patients with advanced liver disease will survive after a major shu…
Frontiers Apr 8, 2026
Corticosteroids in cirrhotic shock show no mortality benefit but increase bleeding and organ failure risk
Gastroenterology Meta-analysis
Corticosteroids in cirrhotic shock show no mortality benefit but increase bleeding and organ failure risk Corticosteroids help resolve shock in cirrhosis patients but don't improve survival
A meta-analysis of 514 cirrhotic patients with septic or distributive shock found low-dose corticosteroids did not reduce in-hospital mortal…
Low-dose corticosteroids help resolve shock in cirrhosis patients but do not improve overall survival and increase bleeding risks.
Apr 6, 2026
Pilot trial finds no between-group muscle mass benefit from HMB supplement in cirrhosis sarcopenia
Gastroenterology RCT
Pilot trial finds no between-group muscle mass benefit from HMB supplement in cirrhosis sarcopenia Small pilot study tests nutritional supplement for muscle loss in liver cirrhosis
A pilot randomized controlled trial of 21 patients with stable decompensated cirrhosis and sarcopenia found no significant between-group dif…
A nutritional supplement with HMB improved leg strength and body composition in cirrhosis patients, though it did not increase overall muscl…
Apr 5, 2026
Continuous terlipressin infusion reduces treatment failure and rebleeding in acute variceal bleeding
Gastroenterology Meta-analysis
Continuous terlipressin infusion reduces treatment failure and rebleeding in acute variceal bleeding Could a different way of giving a bleeding drug save more lives?
A meta-analysis of 6 RCTs (n=494) in cirrhosis patients found continuous terlipressin infusion reduced treatment failure (RR 0.32) and reble…
A slow drip of the bleeding drug terlipressin works better than a quick shot, causing fewer side effects and less rebleeding for patients wi…
Apr 3, 2026
SBRT as bridging therapy in advanced cirrhosis HCC patients shows 67% transplant eligibility at 1 year
Gastroenterology
SBRT as bridging therapy in advanced cirrhosis HCC patients shows 67% transplant eligibility at 1 year Small study explores radiation therapy for liver cancer patients awaiting transplant
A prospective pilot trial in 9 HCC patients with Child-Pugh B8 or worse cirrhosis found that SBRT (40 Gy/5 fractions) as a bridging strategy…
A small study found that focused radiation therapy helped 67% of liver cancer patients with advanced scarring stay eligible for a transplant…
Apr 3, 2026
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis
Gastroenterology
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis Could new drugs finally treat the liver scarring of MASH?
A perspective article reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis (MASH), including metabol…
New metabolic drugs and direct liver therapies offer fresh hope for reversing the scarring that leads to dangerous cirrhosis in MASH patient…
Frontiers Apr 1, 2026
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Gastroenterology Phase II
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis Can an oral drug help people with fatty liver disease? Early safety study begins
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
CT.gov Mar 30, 2026

Questions about Cirrhosis

How common is depression among patients with liver cirrhosis?

Depression is very common in liver cirrhosis, affecting about 37% of patients globally, yet it often goes undiagnosed.

Full answer →
Can the Patient Buddy App help reduce hospital readmissions for my cirrhosis?

Yes, the Patient Buddy App reduced avoidable hospital readmissions in cirrhosis patients by about half in a clinical trial, but discuss with your doctor if it's right for you.

Full answer →